Royal Marsden Hospital / The Royal Marsden NHS Foundation Trust

Real-world 5-year outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC (2026) Girard N, Bar J, Baas P, Chouaid C, Christoph DC, Field JK, Fietkau R, et al. Journal article Clinical management of common toxicities with inhibitors targeting the PI3K/AKT/mTOR pathway in breast cancer (2026) Jhaveri KL, Iyengar NM, Turner NC, Rugo HS, O'Shaughnessy J, Barrios CH, Curigliano G, et al. Journal article, Review article Towards Clinical Translation of Intravoxel Incoherent Motion MRI: Acquisition and Analysis Consensus Recommendations (2026) Sigmund EE, Rauh SS, Iima M, Federau C, Hernando D, Jalnefjord O, Jansen JF, et al. Journal article EP300::VGLL3 fused rhabdomyoblastic tumor revisited: Is the label “rhabdomyosarcoma” justified? (2026) Agaimy A, Thway K, Fisher C Journal article ESTRO recommendations on preoperative radiation therapy in breast cancer: current and future perspectives – Endorsed by ASTRO (2026) Zamagni A, Montero Luis A, Mjaaland I, Chirila ME, Ciervide R, Machiels M, Ratosa I, et al. Journal article Radiotherapy patterns and factors associated with pneumonitis in PACIFIC-R, a real-world study of patients with unresectable stage III non-small-cell lung cancer treated with durvalumab after chemoradiotherapy (2026) Filippi AR, Bar J, Christoph DC, Field JK, Fietkau R, Garassino MC, Garrido P, et al. Journal article What guides regional nodal irradiation in node positive breast cancer following upfront sentinel lymph node biopsy? (2025) Putora PM, Henke G, Beşe N, Boersma L, Coles CE, de Boniface J, Duane F, et al. Journal article First-Line Camizestrant for Emerging ESR1 -Mutated Advanced Breast Cancer. (2025) Bidard FC, Mayer EL, Park YH, Janni W, Ma C, Cristofanilli M, Bianchini G, et al. Journal article Long-Term Efficacy and Safety of Lifileucel Tumor-Infiltrating Lymphocyte Cell Therapy in Patients With Advanced Melanoma: A 5-Year Analysis of the C-144-01 Study. (2025) Medina T, Chesney JA, Kluger HM, Hamid O, Whitman ED, Cusnir M, Thomas SS, et al. Journal article Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma. (2025) Wolchok JD, Chiarion-Sileni V, Rutkowski P, Cowey CL, Schadendorf D, Wagstaff J, Queirolo P, et al. Journal article